ERBB2 and neoplasm: Five mutations in PIK3CA, one in BRCA1 and one in IDH1 found in this study are FDA-recognized biomarkers (level 1) and one ERBB2 mutation is a standard care biomarker (level 2A), predictive of response to FDA-approved drugs in specific tumor types.